0QTA Stock Overview
A clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Guardion Health Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.27 |
52 Week High | US$11.90 |
52 Week Low | US$6.10 |
Beta | 0.86 |
11 Month Change | 0% |
3 Month Change | 0.24% |
1 Year Change | -32.99% |
33 Year Change | -94.91% |
5 Year Change | n/a |
Change since IPO | -97.58% |
Recent News & Updates
Recent updates
Shareholder Returns
0QTA | DE Personal Products | DE Market | |
---|---|---|---|
7D | 0% | -2.3% | 0.8% |
1Y | -33.0% | 3.1% | 6.1% |
Return vs Industry: 0QTA underperformed the German Personal Products industry which returned 12.4% over the past year.
Return vs Market: 0QTA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
0QTA volatility | |
---|---|
0QTA Average Weekly Movement | n/a |
Personal Products Industry Average Movement | 4.2% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0QTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QTA's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 13 | Bret Scholtes | www.guardionhealth.com |
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma.
Guardion Health Sciences, Inc. Fundamentals Summary
0QTA fundamental statistics | |
---|---|
Market cap | €6.74m |
Earnings (TTM) | -€18.83m |
Revenue (TTM) | €10.04m |
0.7x
P/S Ratio-0.4x
P/E RatioIs 0QTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0QTA income statement (TTM) | |
---|---|
Revenue | US$10.95m |
Cost of Revenue | US$6.30m |
Gross Profit | US$4.65m |
Other Expenses | US$25.18m |
Earnings | -US$20.54m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -16.67 |
Gross Margin | 42.44% |
Net Profit Margin | -187.54% |
Debt/Equity Ratio | 0% |
How did 0QTA perform over the long term?
See historical performance and comparison